These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25766669)

  • 21. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
    Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory.
    Sturgeon CM; Duffy MJ; Walker G
    Ann Clin Biochem; 2011 Jul; 48(Pt 4):295-9. PubMed ID: 21746796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    Uyar D; Neary J; Monroe A; Nugent M; Simpson P; Geurts JL
    Gynecol Oncol; 2018 Jun; 149(3):565-569. PubMed ID: 29653687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to the National Institute of Clinical Excellence guidance on parenteral nutrition screening is not enough to improve outcomes.
    Vincent RP; Omar S; Elnenaei MO; Goo CH; Salota R; Wu P; Delaney HL; le Roux CW
    Clin Nutr; 2013 Feb; 32(1):73-6. PubMed ID: 22687466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype.
    Grandi G; Perrone AM; Toss A; Vitagliano A; Friso S; Facchinetti F; Cortesi L; Cascinu S; De Iaco P
    Minerva Med; 2020 Apr; 111(2):133-140. PubMed ID: 32338842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study.
    Scott SE; Gildea C; Nicholson BD; Evans RE; Waller J; Smith D; Purushotham A; Round T
    Lancet Oncol; 2023 Nov; 24(11):1242-1251. PubMed ID: 37922929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective audit of the implementation of the 2-week rule for assessment of suspected urological cancers.
    Coxon JP; Harris HJ; Watkin NA
    Ann R Coll Surg Engl; 2003 Sep; 85(5):347-50. PubMed ID: 14594541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data.
    Barclay M; Gildea C; Poole J; Hirschowitz L; Menon U; Nordin A
    Int J Gynecol Cancer; 2016 Jan; 26(1):56-65. PubMed ID: 26509852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian cancer: risk factors, treatment and management.
    Rooth C
    Br J Nurs; 2013 Sep 12-25; 22(17):S23-30. PubMed ID: 24067270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The two-week wait cancer initiative on oral cancer; the predictive value of urgent referrals to an oral medicine unit.
    Singh P; Warnakulasuriya S
    Br Dent J; 2006 Dec; 201(11):717-20; discussion 714. PubMed ID: 17159958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'Two week wait' standards for suspected gynaecological malignancy. On target, but missing the point?
    Morrison J; Gillespie S; MacKenzie IZ
    J Br Menopause Soc; 2003 Dec; 9(4):170-2. PubMed ID: 15107261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
    Pitynski K; Sporek A; Lipinska I; Banas T; Ludwin A; Bałajewicz-Nowak M
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):766-72. PubMed ID: 26701000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
    Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes for patients referred urgently with suspected head and neck cancer.
    Hobson JC; Malla JV; Sinha J; Kay NJ; Ramamurthy L
    J Laryngol Otol; 2008 Nov; 122(11):1241-4. PubMed ID: 18371234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival in ovarian cancer in Wales: Prior to introduction of all Wales guidelines.
    Shylasree TS; Howells RE; Lim K; Jones PW; Fiander A; Adams M; Evans AS;
    Int J Gynecol Cancer; 2006; 16(5):1770-6. PubMed ID: 17009970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of direct referral for fast CT scan in early lung cancer detection in general practice. A clinical, cluster-randomised trial.
    Guldbrandt LM
    Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP).
    Menon U; Weller D; Falborg AZ; Jensen H; Butler J; Barisic A; Knudsen AK; Bergin RJ; Brewster DH; Cairnduff V; Fourkala EO; Gavin AT; Grunfeld E; Harland E; Kalsi J; Law RJ; Lin Y; Turner D; Neal RD; White V; Harrison S; Reguilon I; Lynch C; Vedsted P;
    Br J Cancer; 2022 Sep; 127(5):844-854. PubMed ID: 35618787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Swanson CL; Kumar A; Maharaj JM; Kemppainen JL; Thomas BC; Weinhold MR; Slaby KM; Mara KC; Wick MJ; Bakkum-Gamez JN
    Gynecol Oncol; 2018 Apr; 149(1):121-126. PubMed ID: 29402500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.